Simile Series B

Synthetic-user startup Simile has secured a $200 million Series B funding round at a $2 billion valuation, just five months after its $100 million Series A. The round was led by Greenoaks with participation from Index Ventures and others, including customer CVS Health Ventures. Simile plans to use these funds to expand its synthetic user simulation platform for marketing and product research.